For most rare diseases and cancers, there are no effective cures yet.
Remarkable advances in the field of life sciences promise to cure the cause of many diseases in the years to come. Advanced treatment approaches such as gene and cell therapies are highly effective because they are targeted, tailored to individual patients or groups of patients, and can even lead to a lasting cure. The approach to each patient is central to the development of new therapies. Access to the latest treatment methods is particularly important at this time.
At the CTGCT Centre of Excellence, we will develop gene and cell therapy technologies, and work to bring advanced medicines to clinical trials for diseases for which we do not yet have effective treatments. This is to improve survival possibilities and quality of life for patients.
Co-funded by the European Union, this project has received funding from Horizon Europe (grant agreement No. 101059842) and UK Research and Innovation (UKRI) under the UK government’s Horizon Europe funding guarantee (grant number 10069462). Views and opinions expressed are of the author(s) only and do not necessarily reflect those of the European Union or the European Research Executive Agency (REA). Neither the European Commission nor the granting authority can be held responsible for them.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Hajdrihova Ulica 19, Ljubljana,ljubljana 1001,slovenia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://ctgct.si/en/
- Keywords
- Saint-Josse-ten-Noode.
- HQ
- Ljubljana, Ljubljana
Ctgct Questions
Ctgct's website is https://ctgct.si/en/
Ctgct's LinkedIn profile is https://si.linkedin.com/company/ctgct
Ctgct has
2 employees.
View email and phone details for 2
employees at Ctgct.
Ctgct's industry is
Biotechnology Research
Ctgct's categories are Biotechnology Research
Ctgct's founding year is 2023
